CD276 and esophageal squamous cell carcinoma: Our study’s use of novel ESCC patient-specific organoid models, both CD276-positive ESCC PSO and the CD276-negative adjacent epithelium PSO (NC PSO), combined with the corresponding primary culture of ESCC cells, may offer a more accurate preclinical method to test the efficacy of CAR-NK against human solid malignancies.